Insulet (Nasdaq:PODD) today initiated a voluntary medical device correction for specific lots of Omnipod 5 insulin pump pods.

Insulet estimates that the pods involved in this correction represent approximately 1.5% of annual production globally.

The company is recalling certain lots of its insulin patch pumps after finding a small tear in the internal tubing may cause insulin to leak inside the pod.

A tear in the tubing may prevent users from getting full insulin doses. So far 18 people have reported serious issues related ...

Insulet has begun recalling specific lots of its Omnipod 5 insulin pumps in the U.S. | The diabetes tech company said it is aware of 18 cases of serious complications related to the under-delivery of ...

Insulet Corp. has identified a manufacturing issue with some of its medical devices that provide automated insulin delivery.

Insulet Corporation (NASDAQ:PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million. Total Omnipod revenue of $422 million marked ...

The FDA has cleared the first tubeless automated insulin delivery system with a smartphone app control. The FDA has cleared Insulet’s Omnipod 5 automated insulin delivery system, marking the first ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has ...

Insulet (NASDAQ:PODD) announced Friday that its tubeless insulin delivery system, Omnipod 5, performed better than conventional insulin pumps in a clinical trial for patients with type 1 diabetes. Its ...

Insulet PODD delivered outstanding first-quarter performance, fueled by the rollout of the new Omnipod 5, which has been on fire since regulatory approval was received last fall. Though management ...